AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045
Statement of unaudited financial results for the quarter and nine months ended 31 December 2022

'Rs in lakhs except for earnings per share data

| Sl No. | Particulars | 3 months ended 31/12/2022 | Previous 3 months ended 30/09/2022 | Corresponding 3 months ended in the previous year 31/12/2021 | 9 months ended 31/12/2022 | 9 months ended 31/12/2021 | Year ended 31/03/2022 |
|---|---|---|---|---|---|---|---|
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Income | | | | | | |
| | a) Revenue from operations | 24,980.85 | 23,612.68 | 20,052.72 | 71,626.73 | 57,363.68 | 80,560.01 |
| | b) Other income | 719.61 | 679.43 | 533.06 | 1,810.46 | 1,107.37 | 1,475.76 |
| | Total income | 25,700.46 | 24,292.11 | 20,585.78 | 73,837.19 | 58,471.05 | 82,035.77 |
| 2 | Expenses | | | | | | |
| | (a) Cost of materials consumed | 2,710.45 | 1,976.26 | 2,657.74 | 6,275.86 | 8,699.07 | 8,961.06 |
| | (b) Purchase of stock-in-trade | 7,424.49 | 7,118.49 | 3,861.97 | 22,074.42 | 14,609.51 | 20,788.07 |
| | (c) Changes in inventories of finished goods, work-in-progress and stock-in-trade | (986.24) | (444.97) | 1,246.99 | (2,215.81) | 1,139.70 | 1,447.01 |
| | (d) Employee benefit expense | 6,268.42 | 6,118.74 | 5,906.28 | 19,224.26 | 17,174.31 | 23,020.62 |
| | (e) Depreciation expense | 413.23 | 328.70 | 350.55 | 1,201.11 | 1,254.20 | 1,694.69 |
| | (f) Allowance for expected credit loss (net) : | 46.00 | (19.26) | 65.69 | 125.74 | 295.18 | 399.93 |
| | (g) Selling, marketing and distribution expense | 2,076.71 | 1,443.24 | 1,445.73 | 4,595.45 | 3,457.98 | 5,071.91 |
| | (h) Other expenses | 3,782.11 | 3,347.72 | 3,382.86 | 11,219.14 | 9,176.51 | 12,253.94 |
| | (i) Finance costs | 19.65 | 16.25 | 22.73 | 54.52 | 74.01 | 94.72 |
| | Total expenses | 21,754.82 | 19,885.17 | 18,959.32 | 62,554.71 | 53,870.48 | 73,732.15 |
| 3 | Profit before tax (1-2) | 3,945.64 | 4,406.94 | 1,626.46 | 11,082.48 | 4,600.57 | 8,303.62 |
| 4 | Tax expense | | | | | | |
| | - Current tax | 984.57 | 1,239.99 | 447.64 | 2,992.07 | 1,341.51 | 2,262.94 |
| | - Deferred tax charge/ (credit) | 30.63 | (89.48) | 36.90 | (111.72) | (101.89) | (118.60) |
| | Total tax expense | 1,015.20 | 1,150.51 | 484.54 | 2,880.35 | 1,239.62 | 2,144.34 |
| 5 | Profit after tax (3-4) | 2,930.44 | 3,256.43 | 1,141.92 | 8,202.13 | 3,360.95 | 6,159.28 |
| 6 | Other comprehensive income/(loss) | | | | | | |
| | A. Items that will not be reclassified to profit or loss | | | | | | |
| | Re-measurement gains/(losses) on post employment benefit obligations | (36.31) | (24.85) | (55.88) | (70.61) | (114.50) | (231.59) |
| | Income tax effect on above | 9.14 | 6.25 | 14.07 | 17.77 | 28.82 | 58.29 |
| | Total other comprehensive income/ (loss), net of income tax | (27.17) | (18.60) | (41.81) | (52.84) | (85.68) | (173.30) |
| | Total comprehensive income for the period (5+6) | 2,903.27 | 3,237.83 | 1,100.11 | 8,149.29 | 3,275.27 | 5,985.98 |
| 7 | Paid-up equity share capital (Face value of Rs 2/- per equity share) | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 | 500.00 |
| 8 | Reserves (excluding revaluation reserves as per balance sheet) | - | - | - | - | - | 50,639.29 |
| 9 | Earnings per equity share of Rs 2/- each (basic and diluted) | 11.72 | 13.03 | 4.57 | 32.81 | 13.44 | 24.64 |

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

**AstraZeneca Pharma India Limited**
**Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**

**Statement of unaudited financial results for the quarter and nine months ended 31 December 2022**

Notes:

1. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
2. The Company has identified 'Healthcare Segment' as its only reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
3. During January 2023, the Company has offered a voluntary separation scheme to certain employees. Management is in the process of determining the amount of settlement which would depend on the final acceptance by the employees. Accordingly, the expenses relating to the scheme will be recognised during the quarter ending 31 March 2023.
4. Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
5. This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 10 February 2023. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 31 December 2022.

**By Order of the Board of Directors**
**For AstraZeneca Pharma India Limited**

**Sanjeev Kumar Panchal**
**Managing Director**

**Place: Bengaluru**
**Date: 10 February, 2023**

Price Waterhouse & Co Chartered Accountants LLP
LLPIN AAC-4362
FRN 304026E/E300009
Bengaluru

**AstraZeneca Pharma India Limited**
**Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045**
**Statement of unaudited financial results for the quarter and nine months ended 31 December 2022**

| | | | | |
|---|---|---|---|---|
| | | | | **Rs in lakhs except for earnings per share data** |
| **Sl No.** | **Particulars** | **3 months ended 31/12/2022** | **Year to date figure for current period ended 31/12/2022** | **Corresponding 3 months ended in the previous year 31/12/2021** |
| | | **Unaudited** | **Unaudited** | **Unaudited** |
| 1 | Total income from operations | 25,700.46 | 73,637.19 | 20,585.78 |
| 2 | Net profit/(loss) for the period from ordinary activities before tax | 3,945.64 | 11,082.48 | 1,626.46 |
| 3 | Net profit/(loss) for the period from ordinary activities after tax | 2,930.44 | 8,202.13 | 1,141.92 |
| 4 | Total comprehensive income for the period after tax | 2,903.27 | 8,149.29 | 1,100.11 |
| 5 | Equity Share Capital | 500.00 | 500.00 | 500.00 |
| 6 | Reserves (excluding revaluation reserves as per balance sheet) | - | - | - |
| 7 | Basic and diluted earnings per share (of Rs 2 each) | 11.72 | 32.81 | 4.57 |

Note:

1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites.(www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).

2. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.

**By Order of the Board of Directors**
**For AstraZeneca Pharma India Limited**

**Sanjeev Kumar Panchal**
**Managing Director**

**Place: Bengaluru**
**Date: 10 February, 2023**